Cognitive-motor Telerehabilitation in MS
Recruiting now · Not applicable
Conditions studied: Multiple Sclerosis
In brief
The primary goal of this project is providing evidence that a home-based combined cognitive-motor training program improves cognition in persons with multiple sclerosis (MS), compared to single cognitive and motor rehabilitation. Secondary goals are to assess the effects on walking performance and to identify the mechanisms of improvement and predictors of treatment response. The main backbone of this project will be a randomized controlled two-centre clinical trial, in which an at-home computerised cognitive-motor rehabilitation program using telemedicine aimed at improving working memory in persons with MS will be evaluated. Based on the information gathered during this trial, possible mechanisms of improvement will be identified by analysing anatomical and neurophysiological changes on structural MRI and resting-state and task-related EEG before and after rehabilitation. Furthermore, factors that can predict treatment response to the rehabilitation program will be identified.
Key facts
- Study ID
- NCT05355389
- Run by
- Universitair Ziekenhuis Brussel
- People needed
- 90
- Starts
- 2022-09-01
- Expected to finish
- 2027-08-31
- Last updated by the study team
- 2026-05-08
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Clinically definite multiple sclerosis (revised McDonald criteria 2017)
- Expanded Disability Status Scale (EDSS) below 6.0
- Digit span backwards z-score between [-3 and -0.5] standard deviations below the median of the normative values
- Age between 18 and 65
- Able to safely perform motor rehabilitation in the home situation (assessed by rehabilitation physician and/or occupational or physiotherapist)
You may not qualify if…
- Cognitive rehabilitation within six months before inclusion
- Inpatient multidisciplinary rehabilitation program within three months before inclusion or planned inpatient program during trial
- Start of or switch in immunomodulator treatment within three months before inclusion
- Less than one month post-exacerbation
- Major psychiatric or medical disorder that could influence cognitive functions
- Combined vision with optimal correction below 0.6 on Snellen Visual Acuity Test
- Unable or unwilling to undergo EEG or MRI
- Refusing informed consent
Where it is running
- Universitair Ziekenhuis Brussel — Brussels, Belgium (enrolling)
- National MS Center Melsbroek — Melsbroek, Belgium (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.